Loading…
Modernizing Retrospective Regulatory Review Act
Legislative Progress
Momentum (last 30 days)
0
score
0 actions · 0 new cosponsors · 0 votes
Speed vs cohort
0pct
0d open
vs 5,674 other S bills in the 119th — cohort avg 32d
No CRS summary is available for this bill yet. The source title, actions, sponsors, and text versions below come from Congress.gov.
These links require the bill number to appear in the filing's source-reported specific issue text. Client expenses and lobbying-firm income are separate disclosure fields.
Filing registrants (1)
2026 · first_quarter · Insurance
Advocated for increased FY27 funding for HRSA's Addiction Medicine Fellowship Program ($30M) and discussed with HRSA officials ways to increase the addiction specialist physician workforce pipeline Advocated for increased FY27 funding for HRSA's Substance Use Disorder Treatment and Recovery Loan Repayment Program ($50M). Advocated for reintroduction of Residential Recovery for Seniors Act. This first-of-its-kind legislation would create a Medicare Part A benefit for residential addiction treatment programs meeting nationally recognized standards, categorized as Level 3.1: Clinically Managed Low-intensity Residential Treatment; Level 3.5: Clinically Managed High-intensity Residential Treatment, and/or Level 3.7: Medically Managed Residential Treatment. It would also establish a prospective payment system for these programs, ensuring that reimbursement for covered residential addiction treatment services is based on pre-determined, fixed amounts. Advocated for reintroduction of S. 644 - the Modernizing Opioid Treatment Access Act, which would allow specially registered addiction specialist physicians to prescribe methadone for OUD that could be accessed at pharmacies. Joined coalition letter urging House and Senate appropriations leaders to pass a full-year Labor, Health and Human Services, Education, and Related Agencies (LHHS) bill for Fiscal Year 2026. Lobbied for the reversal of the administration's significant and abrupt terminations of Substance Abuse and Mental Health Services Administration (SAMHSA) grant funding for addiction care. Joined coalition letter to the U.S. Department of Health and Human Services (HHS) seeking clarification that an existing, single consent for treatment, payment, and health care operations under 42 CFR Part 2 (Part 2) satisfies the H.R. 1 substance use disorder (SUD) community engagement exemption requirements. ASAM has urged the Centers for Medicare & Medicaid Services (CMS) to update Medicare payment and coding policies for outpatient substance use disorder (SUD) treatment to reflect advances in treatment standards. In a letter to CMS Administrator Oz, highlighted several issues necessitated the need to update existing SUD office-based bundled codes, including changes in The ASAM Criteria, the absence of codes to appropriately describe medically managed outpatient treatment, and data showing that millions of Medicare beneficiaries continue to lack access to treatment. Submitted comment letter to the Centers for Medicare and Medicaid Services (CMS) in response to their request for information related to Comprehensive Regulations to Uncover Suspicious Healthcare (CRUSH). In comments to the agency, ASAM emphasized the need to balance protecting patients from fraud, waste, and abuse (FWA) with simultaneously protecting patient access to legitimate treatment options. Joined coalition letter to Members of Congress offering revisions to H.R. 5629 to promote safety, integrated care, affordability, patient choice, and provider diversification in the context of methadone treatment for opioid use disorder. Joined coalition letter to Members of Congress regarding appropriations bills for Fiscal Year (FY) 2027, calling on Congress to provide $310 million in funding for tobacco prevention and cessation initiatives run by the Centers for Disease Control and Prevention (CDC). In a letter to the Centers for Medicare and Medicaid Services (CMS), ASAM urged federal officials not to finalize parts of a newly proposed rule that could make it harder for people to get addiction treatment services. ASAM warned that proposed changes for essential health benefits (EHBs) could unintentionally lead states to scale back coverage for SUD treatment. ASAM also raised alarms about proposed changes to allow marketplace insurers to operate with fewer or even no contracted providers, and remove network adequacy standards like time/distance, and appointment wait times. Sent embargoed copy of ASAM's Implementation Guide for Hospital and Emergency Department Substance Use Disorder Care and cannabis use disorder guideline proposals to ONDCP for its review.
Read twice and referred to the Committee on Homeland Security and Governmental Affairs.
Introduced in Senate
Bills with similar content found using semantic analysis.
Sources: Congress.gov
Client expense: $40,000 · Firm income: Not reported
Government targets: Centers For Medicare and Medicaid Services (CMS), Congressional Budget Office (CBO), Drug Enforcement Administration (DEA), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Health Resources & Services Administration (HRSA), Office of Natl Drug Control Policy (NDCP), SENATE, Substance Abuse & Mental Health Services Administration (SAMHSA)
2026 · first_quarter · Alcohol and Drug Abuse
Advocated for increased FY27 funding for HRSA's Addiction Medicine Fellowship Program ($30M) and discussed with HRSA officials ways to increase the addiction specialist physician workforce pipeline Advocated for increased FY27 funding for HRSA's Substance Use Disorder Treatment and Recovery Loan Repayment Program ($50M). Advocated for reintroduction of Residential Recovery for Seniors Act. This first-of-its-kind legislation would create a Medicare Part A benefit for residential addiction treatment programs meeting nationally recognized standards, categorized as Level 3.1: Clinically Managed Low-intensity Residential Treatment; Level 3.5: Clinically Managed High-intensity Residential Treatment, and/or Level 3.7: Medically Managed Residential Treatment. It would also establish a prospective payment system for these programs, ensuring that reimbursement for covered residential addiction treatment services is based on pre-determined, fixed amounts. Advocated for reintroduction of S. 644 - the Modernizing Opioid Treatment Access Act, which would allow specially registered addiction specialist physicians to prescribe methadone for OUD that could be accessed at pharmacies. Joined coalition letter urging House and Senate appropriations leaders to pass a full-year Labor, Health and Human Services, Education, and Related Agencies (LHHS) bill for Fiscal Year 2026. Lobbied for the reversal of the administration's significant and abrupt terminations of Substance Abuse and Mental Health Services Administration (SAMHSA) grant funding for addiction care. Joined coalition letter to the U.S. Department of Health and Human Services (HHS) seeking clarification that an existing, single consent for treatment, payment, and health care operations under 42 CFR Part 2 (Part 2) satisfies the H.R. 1 substance use disorder (SUD) community engagement exemption requirements. ASAM has urged the Centers for Medicare & Medicaid Services (CMS) to update Medicare payment and coding policies for outpatient substance use disorder (SUD) treatment to reflect advances in treatment standards. In a letter to CMS Administrator Oz, highlighted several issues necessitated the need to update existing SUD office-based bundled codes, including changes in The ASAM Criteria, the absence of codes to appropriately describe medically managed outpatient treatment, and data showing that millions of Medicare beneficiaries continue to lack access to treatment. Submitted comment letter to the Centers for Medicare and Medicaid Services (CMS) in response to their request for information related to Comprehensive Regulations to Uncover Suspicious Healthcare (CRUSH). In comments to the agency, ASAM emphasized the need to balance protecting patients from fraud, waste, and abuse (FWA) with simultaneously protecting patient access to legitimate treatment options. Joined coalition letter to Members of Congress offering revisions to H.R. 5629 to promote safety, integrated care, affordability, patient choice, and provider diversification in the context of methadone treatment for opioid use disorder. Joined coalition letter to Members of Congress regarding appropriations bills for Fiscal Year (FY) 2027, calling on Congress to provide $310 million in funding for tobacco prevention and cessation initiatives run by the Centers for Disease Control and Prevention (CDC). In a letter to the Centers for Medicare and Medicaid Services (CMS), ASAM urged federal officials not to finalize parts of a newly proposed rule that could make it harder for people to get addiction treatment services. ASAM warned that proposed changes for essential health benefits (EHBs) could unintentionally lead states to scale back coverage for SUD treatment. ASAM also raised alarms about proposed changes to allow marketplace insurers to operate with fewer or even no contracted providers, and remove network adequacy standards like time/distance, and appointment wait times. Sent embargoed copy of ASAM's Implementation Guide for Hospital and Emergency Department Substance Use Disorder Care and cannabis use disorder guideline proposals to ONDCP for its review.
Client expense: $40,000 · Firm income: Not reported
Government targets: Centers For Medicare and Medicaid Services (CMS), Congressional Budget Office (CBO), Drug Enforcement Administration (DEA), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Health Resources & Services Administration (HRSA), Office of Natl Drug Control Policy (NDCP), SENATE, Substance Abuse & Mental Health Services Administration (SAMHSA)
2026 · first_quarter · Medicare/Medicaid
Advocated for increased FY27 funding for HRSA's Addiction Medicine Fellowship Program ($30M) and discussed with HRSA officials ways to increase the addiction specialist physician workforce pipeline Advocated for increased FY27 funding for HRSA's Substance Use Disorder Treatment and Recovery Loan Repayment Program ($50M). Advocated for reintroduction of Residential Recovery for Seniors Act. This first-of-its-kind legislation would create a Medicare Part A benefit for residential addiction treatment programs meeting nationally recognized standards, categorized as Level 3.1: Clinically Managed Low-intensity Residential Treatment; Level 3.5: Clinically Managed High-intensity Residential Treatment, and/or Level 3.7: Medically Managed Residential Treatment. It would also establish a prospective payment system for these programs, ensuring that reimbursement for covered residential addiction treatment services is based on pre-determined, fixed amounts. Advocated for reintroduction of S. 644 - the Modernizing Opioid Treatment Access Act, which would allow specially registered addiction specialist physicians to prescribe methadone for OUD that could be accessed at pharmacies. Joined coalition letter urging House and Senate appropriations leaders to pass a full-year Labor, Health and Human Services, Education, and Related Agencies (LHHS) bill for Fiscal Year 2026. Lobbied for the reversal of the administration's significant and abrupt terminations of Substance Abuse and Mental Health Services Administration (SAMHSA) grant funding for addiction care. Joined coalition letter to the U.S. Department of Health and Human Services (HHS) seeking clarification that an existing, single consent for treatment, payment, and health care operations under 42 CFR Part 2 (Part 2) satisfies the H.R. 1 substance use disorder (SUD) community engagement exemption requirements. ASAM has urged the Centers for Medicare & Medicaid Services (CMS) to update Medicare payment and coding policies for outpatient substance use disorder (SUD) treatment to reflect advances in treatment standards. In a letter to CMS Administrator Oz, highlighted several issues necessitated the need to update existing SUD office-based bundled codes, including changes in The ASAM Criteria, the absence of codes to appropriately describe medically managed outpatient treatment, and data showing that millions of Medicare beneficiaries continue to lack access to treatment. Submitted comment letter to the Centers for Medicare and Medicaid Services (CMS) in response to their request for information related to Comprehensive Regulations to Uncover Suspicious Healthcare (CRUSH). In comments to the agency, ASAM emphasized the need to balance protecting patients from fraud, waste, and abuse (FWA) with simultaneously protecting patient access to legitimate treatment options. Joined coalition letter to Members of Congress offering revisions to H.R. 5629 to promote safety, integrated care, affordability, patient choice, and provider diversification in the context of methadone treatment for opioid use disorder. Joined coalition letter to Members of Congress regarding appropriations bills for Fiscal Year (FY) 2027, calling on Congress to provide $310 million in funding for tobacco prevention and cessation initiatives run by the Centers for Disease Control and Prevention (CDC). In a letter to the Centers for Medicare and Medicaid Services (CMS), ASAM urged federal officials not to finalize parts of a newly proposed rule that could make it harder for people to get addiction treatment services. ASAM warned that proposed changes for essential health benefits (EHBs) could unintentionally lead states to scale back coverage for SUD treatment. ASAM also raised alarms about proposed changes to allow marketplace insurers to operate with fewer or even no contracted providers, and remove network adequacy standards like time/distance, and appointment wait times. Sent embargoed copy of ASAM's Implementation Guide for Hospital and Emergency Department Substance Use Disorder Care and cannabis use disorder guideline proposals to ONDCP for its review.
Client expense: $40,000 · Firm income: Not reported
Government targets: Centers For Medicare and Medicaid Services (CMS), Congressional Budget Office (CBO), Drug Enforcement Administration (DEA), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Health Resources & Services Administration (HRSA), Office of Natl Drug Control Policy (NDCP), SENATE, Substance Abuse & Mental Health Services Administration (SAMHSA)
2026 · first_quarter · Budget/Appropriations
Advocated for increased FY27 funding for HRSA's Addiction Medicine Fellowship Program ($30M) and discussed with HRSA officials ways to increase the addiction specialist physician workforce pipeline Advocated for increased FY27 funding for HRSA's Substance Use Disorder Treatment and Recovery Loan Repayment Program ($50M). Advocated for reintroduction of Residential Recovery for Seniors Act. This first-of-its-kind legislation would create a Medicare Part A benefit for residential addiction treatment programs meeting nationally recognized standards, categorized as Level 3.1: Clinically Managed Low-intensity Residential Treatment; Level 3.5: Clinically Managed High-intensity Residential Treatment, and/or Level 3.7: Medically Managed Residential Treatment. It would also establish a prospective payment system for these programs, ensuring that reimbursement for covered residential addiction treatment services is based on pre-determined, fixed amounts. Advocated for reintroduction of S. 644 - the Modernizing Opioid Treatment Access Act, which would allow specially registered addiction specialist physicians to prescribe methadone for OUD that could be accessed at pharmacies. Joined coalition letter urging House and Senate appropriations leaders to pass a full-year Labor, Health and Human Services, Education, and Related Agencies (LHHS) bill for Fiscal Year 2026. Lobbied for the reversal of the administration's significant and abrupt terminations of Substance Abuse and Mental Health Services Administration (SAMHSA) grant funding for addiction care. Joined coalition letter to the U.S. Department of Health and Human Services (HHS) seeking clarification that an existing, single consent for treatment, payment, and health care operations under 42 CFR Part 2 (Part 2) satisfies the H.R. 1 substance use disorder (SUD) community engagement exemption requirements. ASAM has urged the Centers for Medicare & Medicaid Services (CMS) to update Medicare payment and coding policies for outpatient substance use disorder (SUD) treatment to reflect advances in treatment standards. In a letter to CMS Administrator Oz, highlighted several issues necessitated the need to update existing SUD office-based bundled codes, including changes in The ASAM Criteria, the absence of codes to appropriately describe medically managed outpatient treatment, and data showing that millions of Medicare beneficiaries continue to lack access to treatment. Submitted comment letter to the Centers for Medicare and Medicaid Services (CMS) in response to their request for information related to Comprehensive Regulations to Uncover Suspicious Healthcare (CRUSH). In comments to the agency, ASAM emphasized the need to balance protecting patients from fraud, waste, and abuse (FWA) with simultaneously protecting patient access to legitimate treatment options. Joined coalition letter to Members of Congress offering revisions to H.R. 5629 to promote safety, integrated care, affordability, patient choice, and provider diversification in the context of methadone treatment for opioid use disorder. Joined coalition letter to Members of Congress regarding appropriations bills for Fiscal Year (FY) 2027, calling on Congress to provide $310 million in funding for tobacco prevention and cessation initiatives run by the Centers for Disease Control and Prevention (CDC). In a letter to the Centers for Medicare and Medicaid Services (CMS), ASAM urged federal officials not to finalize parts of a newly proposed rule that could make it harder for people to get addiction treatment services. ASAM warned that proposed changes for essential health benefits (EHBs) could unintentionally lead states to scale back coverage for SUD treatment. ASAM also raised alarms about proposed changes to allow marketplace insurers to operate with fewer or even no contracted providers, and remove network adequacy standards like time/distance, and appointment wait times. Sent embargoed copy of ASAM's Implementation Guide for Hospital and Emergency Department Substance Use Disorder Care and cannabis use disorder guideline proposals to ONDCP for its review.
Client expense: $40,000 · Firm income: Not reported
Government targets: Centers For Medicare and Medicaid Services (CMS), Congressional Budget Office (CBO), Drug Enforcement Administration (DEA), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Health Resources & Services Administration (HRSA), Office of Natl Drug Control Policy (NDCP), SENATE, Substance Abuse & Mental Health Services Administration (SAMHSA)
2026 · first_quarter · Medical/Disease Research/Clinical Labs
Advocated for increased FY27 funding for HRSA's Addiction Medicine Fellowship Program ($30M) and discussed with HRSA officials ways to increase the addiction specialist physician workforce pipeline Advocated for increased FY27 funding for HRSA's Substance Use Disorder Treatment and Recovery Loan Repayment Program ($50M). Advocated for reintroduction of Residential Recovery for Seniors Act. This first-of-its-kind legislation would create a Medicare Part A benefit for residential addiction treatment programs meeting nationally recognized standards, categorized as Level 3.1: Clinically Managed Low-intensity Residential Treatment; Level 3.5: Clinically Managed High-intensity Residential Treatment, and/or Level 3.7: Medically Managed Residential Treatment. It would also establish a prospective payment system for these programs, ensuring that reimbursement for covered residential addiction treatment services is based on pre-determined, fixed amounts. Advocated for reintroduction of S. 644 - the Modernizing Opioid Treatment Access Act, which would allow specially registered addiction specialist physicians to prescribe methadone for OUD that could be accessed at pharmacies. Joined coalition letter urging House and Senate appropriations leaders to pass a full-year Labor, Health and Human Services, Education, and Related Agencies (LHHS) bill for Fiscal Year 2026. Lobbied for the reversal of the administration's significant and abrupt terminations of Substance Abuse and Mental Health Services Administration (SAMHSA) grant funding for addiction care. Joined coalition letter to the U.S. Department of Health and Human Services (HHS) seeking clarification that an existing, single consent for treatment, payment, and health care operations under 42 CFR Part 2 (Part 2) satisfies the H.R. 1 substance use disorder (SUD) community engagement exemption requirements. ASAM has urged the Centers for Medicare & Medicaid Services (CMS) to update Medicare payment and coding policies for outpatient substance use disorder (SUD) treatment to reflect advances in treatment standards. In a letter to CMS Administrator Oz, highlighted several issues necessitated the need to update existing SUD office-based bundled codes, including changes in The ASAM Criteria, the absence of codes to appropriately describe medically managed outpatient treatment, and data showing that millions of Medicare beneficiaries continue to lack access to treatment. Submitted comment letter to the Centers for Medicare and Medicaid Services (CMS) in response to their request for information related to Comprehensive Regulations to Uncover Suspicious Healthcare (CRUSH). In comments to the agency, ASAM emphasized the need to balance protecting patients from fraud, waste, and abuse (FWA) with simultaneously protecting patient access to legitimate treatment options. Joined coalition letter to Members of Congress offering revisions to H.R. 5629 to promote safety, integrated care, affordability, patient choice, and provider diversification in the context of methadone treatment for opioid use disorder. Joined coalition letter to Members of Congress regarding appropriations bills for Fiscal Year (FY) 2027, calling on Congress to provide $310 million in funding for tobacco prevention and cessation initiatives run by the Centers for Disease Control and Prevention (CDC). In a letter to the Centers for Medicare and Medicaid Services (CMS), ASAM urged federal officials not to finalize parts of a newly proposed rule that could make it harder for people to get addiction treatment services. ASAM warned that proposed changes for essential health benefits (EHBs) could unintentionally lead states to scale back coverage for SUD treatment. ASAM also raised alarms about proposed changes to allow marketplace insurers to operate with fewer or even no contracted providers, and remove network adequacy standards like time/distance, and appointment wait times. Sent embargoed copy of ASAM's Implementation Guide for Hospital and Emergency Department Substance Use Disorder Care and cannabis use disorder guideline proposals to ONDCP for its review.
Client expense: $40,000 · Firm income: Not reported
Government targets: Centers For Medicare and Medicaid Services (CMS), Congressional Budget Office (CBO), Drug Enforcement Administration (DEA), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Health Resources & Services Administration (HRSA), Office of Natl Drug Control Policy (NDCP), SENATE, Substance Abuse & Mental Health Services Administration (SAMHSA)
2026 · first_quarter · Health Issues
Advocated for increased FY27 funding for HRSA's Addiction Medicine Fellowship Program ($30M) and discussed with HRSA officials ways to increase the addiction specialist physician workforce pipeline Advocated for increased FY27 funding for HRSA's Substance Use Disorder Treatment and Recovery Loan Repayment Program ($50M). Advocated for reintroduction of Residential Recovery for Seniors Act. This first-of-its-kind legislation would create a Medicare Part A benefit for residential addiction treatment programs meeting nationally recognized standards, categorized as Level 3.1: Clinically Managed Low-intensity Residential Treatment; Level 3.5: Clinically Managed High-intensity Residential Treatment, and/or Level 3.7: Medically Managed Residential Treatment. It would also establish a prospective payment system for these programs, ensuring that reimbursement for covered residential addiction treatment services is based on pre-determined, fixed amounts. Advocated for reintroduction of S. 644 - the Modernizing Opioid Treatment Access Act, which would allow specially registered addiction specialist physicians to prescribe methadone for OUD that could be accessed at pharmacies. Joined coalition letter urging House and Senate appropriations leaders to pass a full-year Labor, Health and Human Services, Education, and Related Agencies (LHHS) bill for Fiscal Year 2026. Lobbied for the reversal of the administration's significant and abrupt terminations of Substance Abuse and Mental Health Services Administration (SAMHSA) grant funding for addiction care. Joined coalition letter to the U.S. Department of Health and Human Services (HHS) seeking clarification that an existing, single consent for treatment, payment, and health care operations under 42 CFR Part 2 (Part 2) satisfies the H.R. 1 substance use disorder (SUD) community engagement exemption requirements. ASAM has urged the Centers for Medicare & Medicaid Services (CMS) to update Medicare payment and coding policies for outpatient substance use disorder (SUD) treatment to reflect advances in treatment standards. In a letter to CMS Administrator Oz, highlighted several issues necessitated the need to update existing SUD office-based bundled codes, including changes in The ASAM Criteria, the absence of codes to appropriately describe medically managed outpatient treatment, and data showing that millions of Medicare beneficiaries continue to lack access to treatment. Submitted comment letter to the Centers for Medicare and Medicaid Services (CMS) in response to their request for information related to Comprehensive Regulations to Uncover Suspicious Healthcare (CRUSH). In comments to the agency, ASAM emphasized the need to balance protecting patients from fraud, waste, and abuse (FWA) with simultaneously protecting patient access to legitimate treatment options. Joined coalition letter to Members of Congress offering revisions to H.R. 5629 to promote safety, integrated care, affordability, patient choice, and provider diversification in the context of methadone treatment for opioid use disorder. Joined coalition letter to Members of Congress regarding appropriations bills for Fiscal Year (FY) 2027, calling on Congress to provide $310 million in funding for tobacco prevention and cessation initiatives run by the Centers for Disease Control and Prevention (CDC). In a letter to the Centers for Medicare and Medicaid Services (CMS), ASAM urged federal officials not to finalize parts of a newly proposed rule that could make it harder for people to get addiction treatment services. ASAM warned that proposed changes for essential health benefits (EHBs) could unintentionally lead states to scale back coverage for SUD treatment. ASAM also raised alarms about proposed changes to allow marketplace insurers to operate with fewer or even no contracted providers, and remove network adequacy standards like time/distance, and appointment wait times. Sent embargoed copy of ASAM's Implementation Guide for Hospital and Emergency Department Substance Use Disorder Care and cannabis use disorder guideline proposals to ONDCP for its review.
2025 · third_quarter · Alcohol and Drug Abuse
Sent letter in support of S. 1941- the Cure Hepatitis C Act of 2025, which aims to establish an innovative purchasing model and support a public health infrastructure for a test-to-treat hepatitis C virus (HCV) program, thereby improving patient access to comprehensive treatment. Advocated for increased FY26 funding for HRSA's Addiction Medicine Fellowship Program ($30M) Advocated for increased FY26 funding for HRSA's Substance Use Disorder Treatment and Recovery Loan Repayment Program ($50M). Advocated for reintroduction of Residential Recovery for Seniors Act. This first-of-its-kind legislation would create a Medicare Part A benefit for residential addiction treatment programs meeting nationally recognized standards, categorized as Level 3.1: Clinically Managed Low-intensity Residential Treatment; Level 3.5: Clinically Managed High-intensity Residential Treatment, and/or Level 3.7: Medically Managed Residential Treatment. It would also establish a prospective payment system for these programs, ensuring that reimbursement for covered residential addiction treatment services is based on pre-determined, fixed amounts. Advocated for reintroduction of S. 644 - the Modernizing Opioid Treatment Access Act, which would allow specially registered addiction specialist physicians to prescribe methadone for OUD that could be accessed at pharmacies. Joined coalition letter in opposition of the Administration's broadening of its interpretation of a law that restricts many immigrants living in the United States from receiving federal public benefits. Joined coalition letter supporting a proposed FDA rule that would reduce nicotine levels in cigarettes and other combustible tobacco products. Joined a coalition letter supporting the bipartisan Resident Physician Shortage Reduction Act of 2025 (S. 2493 / H.R. 4731). The bill aims to expand the physician workforce by creating 2,000 new Medicare-supported GME positions annually over seven years, for a total of 14,000 new positions. A portion will be allocated to high-need areas. Submitted comment letter to CMS on its proposed 2026 Medicare Physician Fee Schedule. In its letter, ASAM outlined several suggestions to improve access to behavioral health services, including substance use disorder (SUD) treatment, and to better align treatment codes with this goal in mind. ASAM's recommendations focused on three key areas: outpatient SUD treatment, intensive outpatient treatment, and motivational interviewing. Joined coalition letter to Congressional leadership, supporting the extension of enhanced advance premium tax credits (APTCs). The credits have made health coverage more affordable for the over 24 million people who purchased plans through the Health Insurance Marketplaces. Advocated with CMS for a generous Medicaid work requirement exemption for people with substance use disorder. Endorsed the Michelle Alyssa Go Act that would increase the number of federal Medicaid-eligible in-patient/residential beds for individuals who are seeking treatment for mental health and substance use disorders.
2025 · third_quarter · Health Issues
Sent letter in support of S. 1941- the Cure Hepatitis C Act of 2025, which aims to establish an innovative purchasing model and support a public health infrastructure for a test-to-treat hepatitis C virus (HCV) program, thereby improving patient access to comprehensive treatment. Advocated for increased FY26 funding for HRSA's Addiction Medicine Fellowship Program ($30M) Advocated for increased FY26 funding for HRSA's Substance Use Disorder Treatment and Recovery Loan Repayment Program ($50M). Advocated for reintroduction of Residential Recovery for Seniors Act. This first-of-its-kind legislation would create a Medicare Part A benefit for residential addiction treatment programs meeting nationally recognized standards, categorized as Level 3.1: Clinically Managed Low-intensity Residential Treatment; Level 3.5: Clinically Managed High-intensity Residential Treatment, and/or Level 3.7: Medically Managed Residential Treatment. It would also establish a prospective payment system for these programs, ensuring that reimbursement for covered residential addiction treatment services is based on pre-determined, fixed amounts. Advocated for reintroduction of S. 644 - the Modernizing Opioid Treatment Access Act, which would allow specially registered addiction specialist physicians to prescribe methadone for OUD that could be accessed at pharmacies. Joined coalition letter in opposition of the Administration's broadening of its interpretation of a law that restricts many immigrants living in the United States from receiving federal public benefits. Joined coalition letter supporting a proposed FDA rule that would reduce nicotine levels in cigarettes and other combustible tobacco products. Joined a coalition letter supporting the bipartisan Resident Physician Shortage Reduction Act of 2025 (S. 2493 / H.R. 4731). The bill aims to expand the physician workforce by creating 2,000 new Medicare-supported GME positions annually over seven years, for a total of 14,000 new positions. A portion will be allocated to high-need areas. Submitted comment letter to CMS on its proposed 2026 Medicare Physician Fee Schedule. In its letter, ASAM outlined several suggestions to improve access to behavioral health services, including substance use disorder (SUD) treatment, and to better align treatment codes with this goal in mind. ASAM's recommendations focused on three key areas: outpatient SUD treatment, intensive outpatient treatment, and motivational interviewing. Joined coalition letter to Congressional leadership, supporting the extension of enhanced advance premium tax credits (APTCs). The credits have made health coverage more affordable for the over 24 million people who purchased plans through the Health Insurance Marketplaces. Advocated with CMS for a generous Medicaid work requirement exemption for people with substance use disorder. Endorsed the Michelle Alyssa Go Act that would increase the number of federal Medicaid-eligible in-patient/residential beds for individuals who are seeking treatment for mental health and substance use disorders.
2025 · third_quarter · Medical/Disease Research/Clinical Labs
Sent letter in support of S. 1941- the Cure Hepatitis C Act of 2025, which aims to establish an innovative purchasing model and support a public health infrastructure for a test-to-treat hepatitis C virus (HCV) program, thereby improving patient access to comprehensive treatment. Advocated for increased FY26 funding for HRSA's Addiction Medicine Fellowship Program ($30M) Advocated for increased FY26 funding for HRSA's Substance Use Disorder Treatment and Recovery Loan Repayment Program ($50M). Advocated for reintroduction of Residential Recovery for Seniors Act. This first-of-its-kind legislation would create a Medicare Part A benefit for residential addiction treatment programs meeting nationally recognized standards, categorized as Level 3.1: Clinically Managed Low-intensity Residential Treatment; Level 3.5: Clinically Managed High-intensity Residential Treatment, and/or Level 3.7: Medically Managed Residential Treatment. It would also establish a prospective payment system for these programs, ensuring that reimbursement for covered residential addiction treatment services is based on pre-determined, fixed amounts. Advocated for reintroduction of S. 644 - the Modernizing Opioid Treatment Access Act, which would allow specially registered addiction specialist physicians to prescribe methadone for OUD that could be accessed at pharmacies. Joined coalition letter in opposition of the Administration's broadening of its interpretation of a law that restricts many immigrants living in the United States from receiving federal public benefits. Joined coalition letter supporting a proposed FDA rule that would reduce nicotine levels in cigarettes and other combustible tobacco products. Joined a coalition letter supporting the bipartisan Resident Physician Shortage Reduction Act of 2025 (S. 2493 / H.R. 4731). The bill aims to expand the physician workforce by creating 2,000 new Medicare-supported GME positions annually over seven years, for a total of 14,000 new positions. A portion will be allocated to high-need areas. Submitted comment letter to CMS on its proposed 2026 Medicare Physician Fee Schedule. In its letter, ASAM outlined several suggestions to improve access to behavioral health services, including substance use disorder (SUD) treatment, and to better align treatment codes with this goal in mind. ASAM's recommendations focused on three key areas: outpatient SUD treatment, intensive outpatient treatment, and motivational interviewing. Joined coalition letter to Congressional leadership, supporting the extension of enhanced advance premium tax credits (APTCs). The credits have made health coverage more affordable for the over 24 million people who purchased plans through the Health Insurance Marketplaces. Advocated with CMS for a generous Medicaid work requirement exemption for people with substance use disorder. Endorsed the Michelle Alyssa Go Act that would increase the number of federal Medicaid-eligible in-patient/residential beds for individuals who are seeking treatment for mental health and substance use disorders.
2025 · third_quarter · Medicare/Medicaid
Sent letter in support of S. 1941- the Cure Hepatitis C Act of 2025, which aims to establish an innovative purchasing model and support a public health infrastructure for a test-to-treat hepatitis C virus (HCV) program, thereby improving patient access to comprehensive treatment. Advocated for increased FY26 funding for HRSA's Addiction Medicine Fellowship Program ($30M) Advocated for increased FY26 funding for HRSA's Substance Use Disorder Treatment and Recovery Loan Repayment Program ($50M). Advocated for reintroduction of Residential Recovery for Seniors Act. This first-of-its-kind legislation would create a Medicare Part A benefit for residential addiction treatment programs meeting nationally recognized standards, categorized as Level 3.1: Clinically Managed Low-intensity Residential Treatment; Level 3.5: Clinically Managed High-intensity Residential Treatment, and/or Level 3.7: Medically Managed Residential Treatment. It would also establish a prospective payment system for these programs, ensuring that reimbursement for covered residential addiction treatment services is based on pre-determined, fixed amounts. Advocated for reintroduction of S. 644 - the Modernizing Opioid Treatment Access Act, which would allow specially registered addiction specialist physicians to prescribe methadone for OUD that could be accessed at pharmacies. Joined coalition letter in opposition of the Administration's broadening of its interpretation of a law that restricts many immigrants living in the United States from receiving federal public benefits. Joined coalition letter supporting a proposed FDA rule that would reduce nicotine levels in cigarettes and other combustible tobacco products. Joined a coalition letter supporting the bipartisan Resident Physician Shortage Reduction Act of 2025 (S. 2493 / H.R. 4731). The bill aims to expand the physician workforce by creating 2,000 new Medicare-supported GME positions annually over seven years, for a total of 14,000 new positions. A portion will be allocated to high-need areas. Submitted comment letter to CMS on its proposed 2026 Medicare Physician Fee Schedule. In its letter, ASAM outlined several suggestions to improve access to behavioral health services, including substance use disorder (SUD) treatment, and to better align treatment codes with this goal in mind. ASAM's recommendations focused on three key areas: outpatient SUD treatment, intensive outpatient treatment, and motivational interviewing. Joined coalition letter to Congressional leadership, supporting the extension of enhanced advance premium tax credits (APTCs). The credits have made health coverage more affordable for the over 24 million people who purchased plans through the Health Insurance Marketplaces. Advocated with CMS for a generous Medicaid work requirement exemption for people with substance use disorder. Endorsed the Michelle Alyssa Go Act that would increase the number of federal Medicaid-eligible in-patient/residential beds for individuals who are seeking treatment for mental health and substance use disorders.
2025 · third_quarter · Budget/Appropriations
Sent letter in support of S. 1941- the Cure Hepatitis C Act of 2025, which aims to establish an innovative purchasing model and support a public health infrastructure for a test-to-treat hepatitis C virus (HCV) program, thereby improving patient access to comprehensive treatment. Advocated for increased FY26 funding for HRSA's Addiction Medicine Fellowship Program ($30M) Advocated for increased FY26 funding for HRSA's Substance Use Disorder Treatment and Recovery Loan Repayment Program ($50M). Advocated for reintroduction of Residential Recovery for Seniors Act. This first-of-its-kind legislation would create a Medicare Part A benefit for residential addiction treatment programs meeting nationally recognized standards, categorized as Level 3.1: Clinically Managed Low-intensity Residential Treatment; Level 3.5: Clinically Managed High-intensity Residential Treatment, and/or Level 3.7: Medically Managed Residential Treatment. It would also establish a prospective payment system for these programs, ensuring that reimbursement for covered residential addiction treatment services is based on pre-determined, fixed amounts. Advocated for reintroduction of S. 644 - the Modernizing Opioid Treatment Access Act, which would allow specially registered addiction specialist physicians to prescribe methadone for OUD that could be accessed at pharmacies. Joined coalition letter in opposition of the Administration's broadening of its interpretation of a law that restricts many immigrants living in the United States from receiving federal public benefits. Joined coalition letter supporting a proposed FDA rule that would reduce nicotine levels in cigarettes and other combustible tobacco products. Joined a coalition letter supporting the bipartisan Resident Physician Shortage Reduction Act of 2025 (S. 2493 / H.R. 4731). The bill aims to expand the physician workforce by creating 2,000 new Medicare-supported GME positions annually over seven years, for a total of 14,000 new positions. A portion will be allocated to high-need areas. Submitted comment letter to CMS on its proposed 2026 Medicare Physician Fee Schedule. In its letter, ASAM outlined several suggestions to improve access to behavioral health services, including substance use disorder (SUD) treatment, and to better align treatment codes with this goal in mind. ASAM's recommendations focused on three key areas: outpatient SUD treatment, intensive outpatient treatment, and motivational interviewing. Joined coalition letter to Congressional leadership, supporting the extension of enhanced advance premium tax credits (APTCs). The credits have made health coverage more affordable for the over 24 million people who purchased plans through the Health Insurance Marketplaces. Advocated with CMS for a generous Medicaid work requirement exemption for people with substance use disorder. Endorsed the Michelle Alyssa Go Act that would increase the number of federal Medicaid-eligible in-patient/residential beds for individuals who are seeking treatment for mental health and substance use disorders.
2025 · third_quarter · Insurance
Sent letter in support of S. 1941- the Cure Hepatitis C Act of 2025, which aims to establish an innovative purchasing model and support a public health infrastructure for a test-to-treat hepatitis C virus (HCV) program, thereby improving patient access to comprehensive treatment. Advocated for increased FY26 funding for HRSA's Addiction Medicine Fellowship Program ($30M) Advocated for increased FY26 funding for HRSA's Substance Use Disorder Treatment and Recovery Loan Repayment Program ($50M). Advocated for reintroduction of Residential Recovery for Seniors Act. This first-of-its-kind legislation would create a Medicare Part A benefit for residential addiction treatment programs meeting nationally recognized standards, categorized as Level 3.1: Clinically Managed Low-intensity Residential Treatment; Level 3.5: Clinically Managed High-intensity Residential Treatment, and/or Level 3.7: Medically Managed Residential Treatment. It would also establish a prospective payment system for these programs, ensuring that reimbursement for covered residential addiction treatment services is based on pre-determined, fixed amounts. Advocated for reintroduction of S. 644 - the Modernizing Opioid Treatment Access Act, which would allow specially registered addiction specialist physicians to prescribe methadone for OUD that could be accessed at pharmacies. Joined coalition letter in opposition of the Administration's broadening of its interpretation of a law that restricts many immigrants living in the United States from receiving federal public benefits. Joined coalition letter supporting a proposed FDA rule that would reduce nicotine levels in cigarettes and other combustible tobacco products. Joined a coalition letter supporting the bipartisan Resident Physician Shortage Reduction Act of 2025 (S. 2493 / H.R. 4731). The bill aims to expand the physician workforce by creating 2,000 new Medicare-supported GME positions annually over seven years, for a total of 14,000 new positions. A portion will be allocated to high-need areas. Submitted comment letter to CMS on its proposed 2026 Medicare Physician Fee Schedule. In its letter, ASAM outlined several suggestions to improve access to behavioral health services, including substance use disorder (SUD) treatment, and to better align treatment codes with this goal in mind. ASAM's recommendations focused on three key areas: outpatient SUD treatment, intensive outpatient treatment, and motivational interviewing. Joined coalition letter to Congressional leadership, supporting the extension of enhanced advance premium tax credits (APTCs). The credits have made health coverage more affordable for the over 24 million people who purchased plans through the Health Insurance Marketplaces. Advocated with CMS for a generous Medicaid work requirement exemption for people with substance use disorder. Endorsed the Michelle Alyssa Go Act that would increase the number of federal Medicaid-eligible in-patient/residential beds for individuals who are seeking treatment for mental health and substance use disorders.
Client expense: $40,000 · Firm income: Not reported
Government targets: Centers For Medicare and Medicaid Services (CMS), Congressional Budget Office (CBO), Drug Enforcement Administration (DEA), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Health Resources & Services Administration (HRSA), Office of Natl Drug Control Policy (NDCP), SENATE, Substance Abuse & Mental Health Services Administration (SAMHSA)
Client expense: $70,000 · Firm income: Not reported
Government targets: Centers For Medicare and Medicaid Services (CMS), Congressional Budget Office (CBO), Drug Enforcement Administration (DEA), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Health Resources & Services Administration (HRSA), Office of Natl Drug Control Policy (NDCP), SENATE, Substance Abuse & Mental Health Services Administration (SAMHSA)
Client expense: $70,000 · Firm income: Not reported
Government targets: Centers For Medicare and Medicaid Services (CMS), Congressional Budget Office (CBO), Drug Enforcement Administration (DEA), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Health Resources & Services Administration (HRSA), Office of Natl Drug Control Policy (NDCP), SENATE, Substance Abuse & Mental Health Services Administration (SAMHSA)
Client expense: $70,000 · Firm income: Not reported
Government targets: Centers For Medicare and Medicaid Services (CMS), Congressional Budget Office (CBO), Drug Enforcement Administration (DEA), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Health Resources & Services Administration (HRSA), Office of Natl Drug Control Policy (NDCP), SENATE, Substance Abuse & Mental Health Services Administration (SAMHSA)
Client expense: $70,000 · Firm income: Not reported
Government targets: Centers For Medicare and Medicaid Services (CMS), Congressional Budget Office (CBO), Drug Enforcement Administration (DEA), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Health Resources & Services Administration (HRSA), Office of Natl Drug Control Policy (NDCP), SENATE, Substance Abuse & Mental Health Services Administration (SAMHSA)
Client expense: $70,000 · Firm income: Not reported
Government targets: Centers For Medicare and Medicaid Services (CMS), Congressional Budget Office (CBO), Drug Enforcement Administration (DEA), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Health Resources & Services Administration (HRSA), Office of Natl Drug Control Policy (NDCP), SENATE, Substance Abuse & Mental Health Services Administration (SAMHSA)
Client expense: $70,000 · Firm income: Not reported
Government targets: Centers For Medicare and Medicaid Services (CMS), Congressional Budget Office (CBO), Drug Enforcement Administration (DEA), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Health Resources & Services Administration (HRSA), Office of Natl Drug Control Policy (NDCP), SENATE, Substance Abuse & Mental Health Services Administration (SAMHSA)